Ever Supreme Bio Technology 過去の業績
この会社の最新の決算報告書はまだ処理中です
過去 基準チェック /46
Ever Supreme Bio Technology has been growing earnings at an average annual rate of 58.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 51.5% per year. Ever Supreme Bio Technology's return on equity is 33.1%, and it has net margins of 62%.
主要情報
58.6%
収益成長率
58.7%
EPS成長率
| Biotechs 業界の成長 | 12.2% |
| 収益成長率 | 51.5% |
| 株主資本利益率 | 33.1% |
| ネット・マージン | 62.0% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
収支内訳
Ever Supreme Bio Technology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 824 | 511 | 49 | 103 |
| 31 Mar 24 | 805 | 446 | 49 | 101 |
| 31 Dec 23 | 758 | 539 | 48 | 99 |
| 30 Sep 23 | 683 | 571 | 45 | 95 |
| 30 Jun 23 | 628 | 335 | 41 | 95 |
| 31 Mar 23 | 621 | 326 | 40 | 90 |
| 31 Dec 22 | 628 | 201 | 40 | 91 |
| 30 Sep 22 | 603 | 153 | 45 | 97 |
| 30 Jun 22 | 575 | 348 | 45 | 85 |
| 31 Mar 22 | 513 | 374 | 43 | 87 |
| 31 Dec 21 | 439 | 370 | 45 | 84 |
| 30 Sep 21 | 310 | 261 | 39 | 79 |
| 30 Jun 21 | 193 | 15 | 36 | 90 |
| 31 Mar 21 | 112 | -94 | 35 | 100 |
| 31 Dec 20 | 71 | -107 | 30 | 109 |
| 30 Sep 20 | 53 | -118 | 42 | 119 |
| 30 Jun 20 | 28 | -124 | 43 | 110 |
| 31 Mar 20 | 19 | -102 | 43 | 100 |
| 31 Dec 19 | 11 | -94 | 43 | 95 |
| 30 Sep 19 | 2 | -80 | 30 | 89 |
| 30 Jun 19 | 0 | -85 | 29 | 92 |
| 31 Mar 19 | 0 | -77 | 25 | 83 |
| 31 Dec 18 | 0 | -69 | 21 | 73 |
| 30 Sep 18 | 0 | -56 | 17 | 60 |
| 30 Jun 18 | 0 | -43 | 13 | 46 |
| 31 Mar 18 | 0 | -37 | 12 | 38 |
| 31 Dec 17 | 0 | -31 | 11 | 29 |
質の高い収益: 6712 has a large one-off gain of NT$170.3M impacting its last 12 months of financial results to 30th June, 2024.
利益率の向上: 6712's current net profit margins (62%) are higher than last year (53.3%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 6712 has become profitable over the past 5 years, growing earnings by 58.6% per year.
成長の加速: 6712's earnings growth over the past year (52.5%) is below its 5-year average (58.6% per year).
収益対業界: 6712 earnings growth over the past year (52.5%) exceeded the Biotechs industry 33.2%.
株主資本利益率
高いROE: 6712's Return on Equity (33.1%) is considered high.